All In Biotech

Drug Trial Radar · NCT04335682

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

111

Actual

Start

Aug 17, 2021

Primary completion

Sep 1, 2025

Study completion May 1, 2026

Sponsor

Lead sponsor
Alliance Foundation Trials, LLC.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bayer
First posted
Apr 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with metastatic and non-metastatic castration resistant prostate cancer (CRPC) or metastatic hormone sensitive prostate cancer (HSPC). Approximately 132 patients will be enrolled. Eligible patients will be randomized in a 1:1 fashion to treatment with enzalutamide 160 mg orally daily or darolutamide 600 mg orally twice daily, in combination with standard LHRH agonist based treatment. Cognitive assessments will be performed using modules from Cambridge Neuropsychological Test Automated Battery (CANTAB) an internationally recognized software for assessing cognitive function and impairment.

Conditions

  • Metastatic Prostate Cancer
  • Prostate Cancer Metastatic
  • Prostate Cancer
  • Castrate Resistant Prostate Cancer
  • Hormone Sensitive Prostate Cancer
  • Non-metastatic Prostate Cancer

Interventions

  • DarolutamideDrug

    Patients randomized to darolutamide.

  • EnzalutamideDrug

    Patients randomized to enzalutamide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Maximally Changed Cognitive DomainTime frame: 24 weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of California - San Francisco at Mount Zion

    San Francisco, California

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • University of Kansas Cancer Center

    Fairway, Kansas

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • University of Oklahoma

    Oklahoma City, Oklahoma

  • Froedtert and the Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.